ReviewDrug safety1997
Drug interactions of clinical significance with selective serotonin reuptake inhibitors.
Review in Drug safety, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 76 citations in OpenAlex.
- The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice.International journal of molecular sciences · 2019Review
- Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions.International journal of tryptophan research : IJTR · 2019Review
- Gender-based differences in the antidepressant treatment of patients with depression in German psychiatric practices.German medical science : GMS e-journal · 2016Article
- Serotonin syndrome in the intensive care unit: clinical presentations and precipitating medications.Neurocritical care · 2014Article
- Antidepressant use, depression, and new-onset diabetes among elderly Medicare beneficiaries.Journal of diabetes · 2013Article
- Serotonin syndrome.Ochsner journal · 2013Review
- Brain dopamine and serotonin differ in regulation and its consequences.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Bupropion induced serotonin syndrome: a case report.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2010Article
- SFINX-a drug-drug interaction database designed for clinical decision support systems.European journal of clinical pharmacology · 2009Article
- Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data.British journal of clinical pharmacology · 2008Article
- Role of cytochrome P450 in drug interactions.Nutrition & metabolism · 2008Article
- Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly.Drugs & aging · 2008Review
- Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards.British journal of clinical pharmacology · 2004Article
- Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction.Drug safety · 2004Article
- Moclobemide: therapeutic use and clinical studies.CNS drug reviews · 2003Review
- Development of neuroleptic agents: pharmacogenetics and current safety issues of regulatory concern.Dialogues in clinical neuroscience · 2002Article
- Mechanisms of clinically relevant drug interactions associated with tacrolimus.Clinical pharmacokinetics · 2002Review
- Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it?British journal of clinical pharmacology · 2001Article
- Review
- Drug interactions with cisapride: clinical implications.Clinical pharmacokinetics · 2000Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) have internationally become the accepted 'benchmark' class of antidepressants. It has become clear, however, that there are a number of clinically significant interactions between SSRIs and other medications. The most frequently described interactions are pharmacokinetic, which are far more prevalent than pharmacodynamic interactions. This article details those medications that may interact significantly with the SSRIs, and provides clinical guidelines for minimising the likelihood of such complications. The most common pharmacokinetic interactions are caused by an inhibitory effect of the SSRIs on the hepatic cytochrome P450 (CYP) metabolic system. The SSRIs differ in their potency in inhibiting a number of important CYP isoenzymes (CYP1A2, CYP2C9/10, CYP2C19, CYP2D6 and CYP3A3/4). The major outcome of concern in relation to pharmacodynamic interactions is the development of the 'serotonin syndrome'. While combination of the SSRIs with the irreversible monoamine oxidase inhibitors is the most recognised cause of this syndrome, concurrent administration with moclobemide, tryptophan or selegiline (deprenyl) may also lead to a similar outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.